Dataset Information


Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

ABSTRACT: Oncologic therapy is currently undergoing significant changes. A number of innovative targeted medications currently in clinical development have raised high expectations. With that in mind, discussions about terms such as "clinical benefit" and "clinical relevance" are highly topical. This also applies to further developments in the field of adjuvant systemic therapies for early-stage breast cancer. As the treatment aim is curative, assessment of the clinical benefit of adjuvant therapies must be largely based on efficacy outcomes. The focus must be on improving disease-free survival rates and lowering the risk of recurrence. Because of the current low mortality rates, statements about overall survival rates are only possible after very long observation periods. Consequently, new drugs in adjuvant therapies should be considered as offering a clinical benefit, if they reduce the risk of recurrence below current low levels of risk. The evidence for established adjuvant therapy standards in early-stage breast cancer can be used as objective criteria for comparison. This review article considers the requirements for clinical benefit of new adjuvant therapies for early breast cancer, based on examples from adjuvant endocrine therapy, adjuvant polychemotherapy and adjuvant anti-HER2 therapy.


PROVIDER: S-EPMC5658231 | BioStudies | 2017-01-01T00:00:00Z


REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4538915 | BioStudies
2010-01-01 | S-EPMC2882502 | BioStudies
1000-01-01 | S-EPMC2738431 | BioStudies
2017-01-01 | S-EPMC5459968 | BioStudies
2015-01-01 | S-EPMC4743500 | BioStudies
1000-01-01 | S-EPMC6102296 | BioStudies
2018-01-01 | S-EPMC6001757 | BioStudies
2019-01-01 | S-EPMC6394785 | BioStudies
2012-04-19 | GSE37405 | GEO
2020-01-01 | S-EPMC6777230 | BioStudies